http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2552627-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10affa7be6b57ed4f9cbb87bf1f5eb4e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4709 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2010-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f38e67936b073e1a9d0a13709feab086 |
| publicationDate | 2015-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2552627-T3 |
| titleOfInvention | Methods and reagents for enhanced detection of beta amyloid peptides |
| abstract | Method for the diagnosis in a subject of a neurodegenerative disease, for the detection of an earlier stage of a neurodegenerative disease or for the distinction of a neurodegenerative disease of a stage prior to said neurodegenerative disease, comprising the steps of (i) determining one or more parameters selected from the group of (a) the level of one or more free beta amyloid peptides in a biological sample of said subject, (b) the aggregate levels of one or more free amyloid peptides in a biological sample of said subject and of said one or more beta amyloid peptides associated with the macromolecular components present in said biological sample, wherein said aggregate levels are determined by quantifying the amount of said one or more beta amyloid peptides in the cell-free fraction of said sample after contacting said sample with a protein solubilizing agent under conditions to promote the dissociation of the beta amyloid peptide or peptides from the components present in the biological sample, (c) the level of one or more beta amyloid peptides associated with the cells in a biological sample of said subject, wherein said level is determines by isolating the cell fraction of said biological sample, the contact of said cell fraction of said sample with a protein solubilizing agent under conditions suitable to promote the dissociation of the amyloid beta peptide or peptides from the cells present in the sample and (ii) compare the value of at least one of the parameters (b) or (c) or the value of a calculated parameter resulting from arithmetically combining at least two of the parameters (a) to (c) with a reference value corresponding to the value of said parameters (b) or (c), or said parameter calculated in a reference sample and (iii) diagnose neurodegenerative disease, detect a stage prior to a neurodegenerative disease or distinguish a neurodegenerative disease from a stage prior to said neurodegenerative disease when there is an alteration in the value of the parameter or in the value of the parameter calculated with respect to the reference value, in which the biological sample it is plasma or blood and in which the parameters determined in step (i) are one or more of the parameters selected from group (a) 1ab40, corresponding to the level of free ABETA40 peptide in a biological sample of said subject, (b) 1ab42, corresponding to the level of free ABETA42 peptide in a biological sample of said subject, (c) 2ab40, corresponding to the aggregate levels of free ABETA40 peptide in a biological sample of said subject and of ABETA40 peptide associated with the components of said biological sample , wherein 2ab40 is determined by quantifying the amount of ABETA40 peptide in said sample after putting e n contacting said sample with a protein solubilizing agent under conditions suitable to promote the dissociation of the ABETA40 peptide from the components present in the biological sample, (d) 2ab42, corresponding to the aggregate level of free ABETA42 peptide in a biological sample of said subject and of ABETA42 peptide associated with the components of said biological sample, wherein 2ab42 is determined by quantifying the amount of ABETA42 peptide in said sample after contacting said sample with a protein solubilizing agent under conditions suitable to promote dissociation of the ABETA42 peptide of the components present in the biological sample, (e) 3ab40, corresponding to the level of the ABETA40 peptide associated with the cells in a biological sample of said subject, in which 3ab40 is determined by quantifying the amount of ABETA40 peptide after contacting the cell fraction of said sample b iological with a protein solubilizing agent under conditions suitable to promote the dissociation of beta amyloid peptides from the cells present in the sample and (f) 3ab42, corresponding to the level of ABETA42 peptide associated with the cells in a biological sample of said subject, wherein 3ab42 is determined by quantifying the amount of ABETA42 peptide after contacting the cell fraction of said biological sample with a protein solubilizing agent under conditions suitable to promote the dissociation of the amyloid beta peptides from the cells present in the sample. |
| priorityDate | 2009-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 65.